Ann: Phosphagenics Receives Further Arbitration Process Update, page-100

Even $20-$30m US will make a huge difference, particularly in regards to not needing to raise funds. No doubt the subdued share price is partly due to the reality of the need for a cash raise if unsuccessful. So a positive outcome abolishes that concern immediately.
Then you’ve got the implication of cash backing value and THEN pipeline products can be factored in, no more so than daptomycin then propofol etc etc.
Generally things snowball in one direction quickly. If we get it going our way, that ball will grow quickly in the right direction in my opinion.